Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients

Cancer Research

Volumn 69, Issue 18, 2009, Pages 7338-7346

  Passoni, Lorena ^a   Longo, Luca ^b,c   Collini, Paola ^a   Coluccia, Addolorata Maria Luce ^e   Bozzi, Fabio ^a   Podda, Marta ^a   Gregorio, Andrea ^d   Gambini, Claudio ^d   Garaventa, Alberto ^d   Pistoia, Vito ^d   Del Grosso, Federica ^c   Tonini, Gian Paolo ^c   Cheng, Mangeng ^f   Gambacorti Passerini, Carlo ^g   Anichini, Andrea ^a   Fossati Bellani, Franca ^a   Di Nicola, Massimo ^a   Luksch, Roberto ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Italian Neuroblastoma Foundation   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d G GASLINI INSTITUTE   (Italy)

^e NATIONAL NANOTECHNOLOGY LABORATORY   (Italy)

^f CEPHALON INC   (United States)

^g UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; MESSENGER RNA; MUTANT PROTEIN;

ADVANCED CANCER; ARTICLE; CARCINOGENESIS; CELL CYCLE ARREST; CELL DEATH; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GERM LINE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; METASTASIS; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION; WILD TYPE;

CARBAZOLES; CELL DEATH; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DISEASE PROGRESSION; DOWN-REGULATION; ENZYME ACTIVATION; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; NEUROBLASTOMA; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 70349733112     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4419     Document Type: Article

References (37)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-216 (Pubitemid 37328872)
2. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106-2120
3. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-1173
4. Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. J Clin Oncol 2000;18:18-26. (Pubitemid 30036332)
5. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008;8:11-23.
6. Coluccia AM, Gunby RH, Tartari CJ, Scapozza L, Gambacorti-Passerini C, Passoni L. Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy. Expert Opin Ther Targets 2005;9:515-532 (Pubitemid 40883151)
7. Gouzi JY, Moog-Lutz C, Vigny M, Brunet-de Carvalho N. Role of the subcellular localization of ALK tyrosine kinase domain in neuronal differentiation of PC12 cells. J Cell Sci 2005;118:5811-5823 (Pubitemid 43079274)
8. Mi R, Chen W, Hoke A. Pleiotrophin is a neurotrophic factor for spinal motor neurons. Proc Natl Acad Sci U S A 2007;104:4664-4669 (Pubitemid 47186282)
9. Motegi A, Fujimoto J, Kotani M, Sakuraba H, Yamamoto T. ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth. J Cell Sci 2004;117:3319-3329 (Pubitemid 39139916)
10. Souttou B, Carvalho NB, Raulais D, Vigny M. Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway. J Biol Chem 2001;276:9526-9531 (Pubitemid 37385543)
11. Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett 2004;204:127-143 (Pubitemid 38167717)
12. De Preter K, Vandesompele J, Heimann P, et al. Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. Genome Biol 2006;7:R84. (Pubitemid 44650258)
13. Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930-935
14. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455:971-974
15. George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008;455:975-978
16. Janoueix-Lerosey I, Lequin D, Brugieres L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455:967-970
17. Caren H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 2008;416:153-159
18. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-1477 (Pubitemid 23228250)
19. Wan W, Albom MS, Lu L, et al. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood 2006;107:1617-1623 (Pubitemid 43242400)
20. van de Wetering M, Oving I, Muncan V, et al. Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep 2003;4:609-615 (Pubitemid 36939953)
21. Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999;86:364-372 (Pubitemid 29327594)
22. Moog-Lutz C, Degoutin J, Gouzi JY, et al. Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J Biol Chem 2005;280:26039-26048 (Pubitemid 41022195)
23. Powers C, Aigner A, Stoica GE, McDonnell K, Wellstein A. Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J Biol Chem 2002;277:14153-14158 (Pubitemid 34968027)
24. Stoica GE, Kuo A, Aigner A, et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem 2001;276:16772-16779 (Pubitemid 37411470)
25. Lu KV, Jong KA, Kim GY, et al. Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J Biol Chem 2005;280:26953-26964
26. Perez-Pinera P, Zhang W, Chang Y, Vega JA, Deuel TF. Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase β/ζ signaling pathway: an alternative mechanism of receptor tyrosine kinase activation. J Biol Chem 2007;282:28683-28690 (Pubitemid 47606064)
27. Osajima-Hakomori Y, Miyake I, Ohira M, Nakagawara A, Nakagawa A, Sakai R. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol 2005;167:213-222 (Pubitemid 40884782)
28. Teresi RE, Zbuk KM, Pezzolesi MG, Waite KA, Eng C. Cowden syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation. Am J Hum Genet 2007;81:756-767 (Pubitemid 47596543)
29. Zhou XP, Waite KA, Pilarski R, et al. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet 2003;73:404-411 (Pubitemid 36921003)
30. Miyake I, Hakomori Y, Shinohara A, et al. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene 2002;21:5823-5834 (Pubitemid 35007232)
31. Serresi M, Piccinini G, Pierpaoli E, Fazioli F. A ligand-inducible anaplastic lymphoma kinase chimera is endocytosis impaired. Oncogene 2004;23:1098-1108 (Pubitemid 38269963)
32. Bonvini P, Gastaldi T, Falini B, Rosolen A. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. Cancer Res 2002;62:1559-1566 (Pubitemid 34407823)
33. Lamant L, Pulford K, Bischof D, et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 2000;156:1711-1721 (Pubitemid 30646709)
34. London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005;23:6459-6465 (Pubitemid 46190236)
35. Burgues O, Navarro S, Noguera R, et al. Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stromapoor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry. Virchows Arch 2006;449:410-420 (Pubitemid 44451315)
36. De Bernardi B, Nicolas B, Boni L, et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 2003;21:1592-1601 (Pubitemid 46594114)
37. McDermott U, Iafrate AJ, Gray NS, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008;68:3389-3395